Recombinant birch pollen

BIOLOGICAL2 trials

Sponsors

Allergopharma GmbH & Co. KG

Conditions

Birch Pollen Allergy

Phase 2

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

CompletedNCT00266526

Allergopharma GmbH & Co. KGBirch Pollen Allergy

Start: 2003-07-31End: 2005-07-31Updated: 2013-03-04

Phase 3

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

CompletedNCT00309062

Allergopharma GmbH & Co. KGBirch Pollen Allergy

Start: 2003-12-31End: 2009-06-30Updated: 2013-03-11

Related Papers

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial

Clinical and Translational Allergy2015-01-0153 citations